Smith & Nephew plc (LON:SN)
London · Delayed Price · Currency is GBP · Price in GBX | Market Cap | 10.48B |
| Revenue (ttm) | 4.33B |
| Net Income (ttm) | 358.03M |
| Shares Out | 849.72M |
| EPS (ttm) | 0.41 |
| PE Ratio | 30.31 |
| Forward PE | 14.98 |
| Dividend | 0.28 (2.31%) |
| Ex-Dividend Date | Oct 2, 2025 |
| Volume | 5,360,177 |
| Average Volume | 2,504,979 |
| Open | 1,226.00 |
| Previous Close | 1,230.50 |
| Day's Range | 1,221.00 - 1,236.00 |
| 52-Week Range | 937.80 - 1,441.50 |
| Beta | 0.66 |
| RSI | 44.17 |
| Earnings Date | Mar 2, 2026 |
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom, the United States, and internationally. It operates in three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction proced... [Read more]
Financial Performance
In 2024, Smith & Nephew's revenue was $5.81 billion, an increase of 4.70% compared to the previous year's $5.55 billion. Earnings were $412.00 million, an increase of 56.65%.
Financial numbers in USD Financial StatementsNews
Smith & Nephew plc (SNN) Analyst/Investor Day Transcript
Smith & Nephew plc (SNN) Analyst/Investor Day Transcript
Smith & Nephew plc (SNN) Analyst/Investor Day - Slideshow
Smith & Nephew plc (SNN) Analyst/Investor Day Transcript
Anglo American’s merger bonus was a pay wheeze too far | Nils Pratley
Miner will have to do things by the book after ditching plan to pay bosses millions in bonuses after Teck deal Anglo American drops plan to pay bosses millions in bonuses Shareholder rebellions over e...
UK Stock Market News: Smith & Nephew, Unilever, Oxford Nanopore
Smith & Nephew unveils RISE strategy with upgraded guidance, Unilever completes ice cream demerger, Oxford Nanopore names veteran CEO
Smith & Nephew boosts 2025 cashflow forecast and unveils medium-term targets
British medical products maker Smith & Nephew raised its 2025 free cash flow forecast to around $800 million and unveiled new medium-term targets ahead of its Capital Markets Day Event on Monday.
Smith & Nephew (SNN) Analyst Rating Update: Target Price Lowered | SNN Stock News
Smith & Nephew (SNN) Analyst Rating Update: Target Price Lowered | SNN Stock News
Smith & Nephew is Now Oversold (SNN)
Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a tec...
Smith & Nephew plc (SNN) Q3 2025 Sales Call Transcript
Smith & Nephew plc (SNN) Q3 2025 Sales/ Trading Statement Call - Slideshow
Smith & Nephew: Expensive Valuations And Muted Growth May Dampen Upcoming Q3 Earnings Release
Discover why Smith & Nephew (SNN) earns a 'Hold' rating amid valuation concerns and resistance levels. Click here to read my analysis of Smith & Nephew stock.
Smith+Nephew comparative study1 shows PICO◊ sNPWT (-80 mmHg) delivers superior performance in relation to wound dehiscence and reduces healthcare costs across cardiovascular and orthopedic surgery versus PrevenaTM -125 mmHg sNPWT
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces findings from a newly published, first-of-its-kind comparative study of single-use negative pressure wound thera...
UFC® and Smith+Nephew announce multi-year extension of partnership
Smith+Nephew to continue as UFC's Preferred Sports Medicine Technology Partner Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, and UFC the world's premier mixed martial arts or...
Smith & Nephew (SNN) Downgraded to 'Market Perform' by Bernstein | SNN Stock News
Smith & Nephew (SNN) Downgraded to 'Market Perform' by Bernstein | SNN Stock News
Smith+Nephew announce latest scientific data supporting new ALLEVYN™ COMPLETE CARE 5-Layer Foam Dressing for pressure injury prevention
Smith+Nephew (NYSE:SNN; LSE:SN), the global medical technology business, is pleased to announce exciting new data from Professor Amit Gefen and his research group published in the International Wound ...
Smith+Nephew launches CORIOGRAPH™ Pre-Op Planning and Modeling Services for total shoulder arthroplasty
Completes the CORIOGRAPH Services portfolio which also includes solutions for knee and hip arthroplasty Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the laun...
Ex-Dividend Reminder: ESAB, Sylvamo and Smith & Nephew
Looking at the universe of stocks we cover at Dividend Channel, on 10/3/25, ESAB Corp (Symbol: ESAB), Sylvamo Corp (Symbol: SLVM), and Smith & Nephew plc (Symbol: SNN) will all trade ex-dividend for t...
Smith & Nephew Reaches Analyst Target Price
In recent trading, shares of Smith & Nephew plc (Symbol: SNN) have crossed above the average analyst 12-month target price of $35.55, changing hands for $36.29/share. When a stock reaches the target a...
Smith & Nephew (SNN) CFO Relocates to U.S. to Drive Growth
Smith & Nephew (SNN) CFO Relocates to U.S. to Drive Growth
Smith & Nephew CFO shifts base to U.S. from U.K.
Smith & Nephew (SNN) Upgraded to Buy: What Does It Mean for the Stock?
Smith & Nephew (SNN) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Smith+Nephew (SNN) Highlights Advances in REGENETEN Implant Technology
Smith+Nephew (SNN) Highlights Advances in REGENETEN Implant Technology
Smith+Nephew unveils major clinical evidence and patient access updates for its REGENETEN™ Bioinductive Implant
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces new evidence and market updates that highlight the clinical performance of its REGENETEN Bioinductive Implant an...
What Does the Market Think About Smith & Nephew?
Smith & Nephew's (NYSE: SNN) short percent of float has risen 6.56% since its last report. The company recently reported that it has 2.84 million shares sold short , which is 0.65% of all regular sha...
Smith+Nephew extends Advanced Wound Bioactives portfolio with US launch of CENTRIO Platelet-Rich-Plasma System
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces the launch of the CENTRIO Platelet-Rich-Plasma (PRP) System, a biodynamic hematogel derived from a patient's own...